Cannabis Science , a US biotech company, is negotiating with commercialisation groups to make its anti-cancer formulations available for public viewing, the firm has announced.
The collection of data will be a “major contribution” to the body of evidence that will guide its investigative new drug applications to the US Food and Drug Administration for approval, the company said in a statement.
Cannabis is well known for its holistic functions, but recent scientific studies have demonstrated the ability of cannabinoids to kill cancer cells in animals and tissue culture.
Cannabis Science’s goal is to coordinate clinical partnerships and patient care with its standardised product line in Colorado, and to gather data that supports the use of cannabis extracts.
Cancer drugs tend to be hugely expensive, however, cannabis products, if made available to the public, are expected to cost far less.